Juliet Tammenoms Bakker net worth and biography

Juliet Bakker Biography and Net Worth

Director of RxSight

Ms. Tammenoms Bakker has served as a member of our Board since June 2015. Ms. Tammenoms Bakker co-founded Longitude Capital, a healthcare venture capital firm, where she has served as a Managing Director since 2006. Prior to Longitude, Ms. Tammenoms Bakker served as a Managing Director of Pequot Ventures, where she founded the life sciences investment practice. Prior to Pequot Ventures, Ms. Tammenoms Bakker was an equity research analyst with Banque Paribas. Ms. Tammenoms Bakker currently serves on the boards of directors of Ceribell, Inc. (NASDAQ:CBLL) and other privately held healthcare companies. Ms. Tammenoms Bakker previously served on the boards of directors of over twenty companies including Eargo, Inc. (NASDAQ:EAR), Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), and Venus concept Inc. (NASDAQ:VERO). Ms. Tammenoms Bakker holds an M.P.A. from the Harvard Kennedy School and a B.Sc. from the College of Agriculture and Life Sciences at Cornell University, or CALS, and she currently serves as a Trustee on the Board of Trustees at Cornell University.

What is Juliet Tammenoms Bakker's net worth?: The estimated net worth of Juliet Tammenoms Bakker is at least $363,827.20 as of February 12th, 2024. Bakker owns 25,840 shares of RxSight stock worth more than $363,827 as of April 14th. This net worth approximation does not reflect any other assets that Bakker may own. Learn More about Juliet Tammenoms Bakker's net worth.
How do I contact Juliet Tammenoms Bakker?: The corporate mailing address for Bakker and other RxSight executives is , , . RxSight can also be reached via phone at 949-521-7830 and via email at ir@rxsight.com. Learn More on Juliet Tammenoms Bakker's contact information.
Has Juliet Tammenoms Bakker been buying or selling shares of RxSight?: Juliet Tammenoms Bakker has not been actively trading shares of RxSight during the last quarter. Most recently, on Wednesday, February 14th, Bakker Juliet Tammenoms bought 4,000 shares of RxSight stock. The stock was acquired at an average cost of $51.29 per share, with a total value of $205,160.00. Following the completion of the transaction, the director now directly owns 29,840 shares of the company's stock, valued at $1,530,493.60. Learn More on Juliet Tammenoms Bakker's trading history.
Who are RxSight's active insiders?: RxSight's insider roster includes Julie Andrews (Director), Juliet Bakker (Director), Jesse Corley (Director), Tamara Fountain (Director), Ilya Goldshleger (Insider), Ilya Goldshleger (Insider), M Kurtz (CEO), William Link (Director), Shweta Maniar (Director), Shelley Thunen (CFO), Robert Warner (Director), and Eric Weinberg (Insider). Learn More on RxSight's active insiders.
Are insiders buying or selling shares of RxSight?: In the last year, RxSight insiders bought shares 2 times. They purchased a total of 12,554 shares worth more than $549,098.81. In the last year, insiders at the sold shares 28 times. They sold a total of 160,951 shares worth more than $8,269,376.44. The most recent insider tranaction occured on March, 12th when Director Tamara Fountain sold 7,000 shares worth more than $179,970.00. Insiders at RxSight own 9.4% of the company. Learn More about insider trades at RxSight.
Information on this page was last updated on 3/12/2025.

Juliet Tammenoms Bakker Insider Trading History at RxSight

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/14/2024	Buy	4,000	$51.29	$205,160.00	29,840
2/12/2024	Buy	4,000	$50.38	$201,520.00	25,840
11/28/2023	Sell	145,068	$29.62	$4,296,914.16	349,245
11/14/2023	Sell	100,000	$27.13	$2,713,000.00	894,313
9/11/2023	Sell	2,950	$30.01	$88,529.50	20,223
9/7/2023	Sell	19,967	$30.10	$601,006.70	33,206
8/25/2023	Sell	16,208	$29.25	$474,084.00	53,173
8/17/2023	Sell	18,484	$30.06	$555,629.04	83,062
2/10/2023	Buy	480,000	$12.50	$6,000,000.00	980,000

Juliet Tammenoms Bakker Buying and Selling Activity at RxSight

RxSight Company Overview

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Today's Range

Now: $14.35

$13.97

$14.61

50 Day Range

MA: $25.63

$14.08

$34.26

2 Week Range

Now: $14.35

$13.50

$66.54

Volume

330,834 shs

Average Volume

604,029 shs

Market Capitalization

$581.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26